KATIE GERVASINI: Open Payments
NPI 1952054496 · SOUTH KINGSTOWN, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$718 in 24 payments from 8 companies in 2025. Trend: 2023 $0 · 2024 $272 · 2025 $718
Food & beverage: $718
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 5 | $210 |
| QOL Medical, LLC | 5 | $144 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $109 |
| Janssen Biotech, Inc. | 3 | $78 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $73 |
| Ardelyx, Inc. | 2 | $49 |
| Lilly USA, LLC | 1 | $28 |
| ABBVIE INC. | 1 | $27 |
Products named: REZDIFFRA, Sucraid, TREMFYA, ENTYVIO, XIFAXAN, IBSRELA, GATTEX, OMVOH.
Industry payments across RI — which companies pay providers there.
